April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
A Drug Eluting Contact Lens
Author Affiliations & Notes
  • J. B. Ciolino
    Cornea, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
  • T. R. Hoare
    Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
  • C. H. Dolhman
    Cornea, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
  • I. Behlau
    Cornea, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
    Schepens Eye Research Institute, Boston, Massachusetts
  • N. G. Iwata
    Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
  • R. Langer
    Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
  • D. S. Kohane
    Anesthesiology, Childen's Hospital, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  J.B. Ciolino, None; T.R. Hoare, None; C.H. Dolhman, None; I. Behlau, None; N.G. Iwata, None; R. Langer, None; D.S. Kohane, None.
  • Footnotes
    Support  NIGMS GM073626 (DSK), Fight for Sight Grant-in –Aid (IB), National Institute of Health grant EB-00351 (RL), CIMIT / J&J Young Investigator Award (DSK), and by the Boston KPro Fund.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5638. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. B. Ciolino, T. R. Hoare, C. H. Dolhman, I. Behlau, N. G. Iwata, R. Langer, D. S. Kohane; A Drug Eluting Contact Lens. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5638.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To formulate and characterize a drug-eluting contact lens designed to provide extended, controlled release of a drug.

Methods: : Prototype contact lenses were created by coating PLGA (Poly[lactic-co-glycolic acid]) films containing test compounds with pHEMA (poly[hydroxyethyl methacrylate]) by ultraviolet light polymerization. The films, containing encapsulated fluorescein or ciprofloxacin, were characterized by scanning electron microscopy. Release studies were conducted in phosphate buffered saline at 37°C with continuous shaking. Ciprofloxacin eluted from the contact lens was studied in an antimicrobial assay to verify antimicrobial effectiveness.

Results: : After a brief and minimal initial burst, the prototype contact lenses demonstrated controlled release of the molecules studied, with zero-order release kinetics under infinite sink conditions for over 4 weeks for both Ciprofloxacin (Figure 1) and Fluorescein (Figure 2). The rate of drug release was controlled by changing either the ratio of drug to PLGA or the molecular weight of the PLGA employed. Both the PLGA and the pHEMA affected release kinetics (Figure 2). Ciprofloxacin released from the contact lenses inhibited ciprofloxacin-sensitive Staphylococcus aureus at all time-points tested.

Conclusions: : A prototype contact lens for sustained drug release consisting of a thin drug-PLGA film coated with pHEMA could potentially be used as a platform for ocular drug delivery with widespread therapeutic applications.

Keywords: contact lens • antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×